In COAD, the authors explained that the PTX3 gene was silenced by DNA methylation of the promoter and a putative enhancer, while increased PTX3 plasma levels reasonably reflected cancer-related inflammation associated with tumor growth [6]. The gene discussed is PTX3; the disease is cancer.